scispace - formally typeset
M

Marc A. Pfeffer

Researcher at Brigham and Women's Hospital

Publications -  815
Citations -  143710

Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.

Papers
More filters
Patent

Use of angiotensin antagonist (at1) for reducing post myocardial infarct mobidity and mortality

TL;DR: In this paper, a method for treating a human survivor of a heart attack and providing further improvement in survival following the heart attack by the early initiation and long-term administration of a renin-angiotensin system inhibitor, preferably an angio-ensin converting enzyme inhibitor.
Journal ArticleDOI

Right Ventricular Function and Coupling to Pulmonary Circulation in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Trial.

TL;DR: The PARAGON-HF trial as mentioned in this paper was used to assess the clinical implications of right ventricular (RV) function and the association with N-terminal pro-B-type natriuretic-peptide (NT-proBNP) and the risk for adverse events among left ventricular ejection fraction (HFpEF) patients.
Journal ArticleDOI

OR-37: Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension. Results of the conduit hemodynamics of omapatrilat international research (CHOIR) study

TL;DR: Greater reductions in pulse pressure and Zc in hypertensive subjects treated with omapatrilat compared with enalapril suggest that aortic stiffness is maintained by specific, partially reversible mechanisms and underscore a potential role for pharmacological modulation of natriuretic peptides in the treatment of hypertension.
Journal ArticleDOI

Candesartán reduce moderadamente los ingresos hospitalarios en pacientes con insuficiencia cardíaca crónica y función sistólica preservada

TL;DR: Los pacientes fueron aleatorizados para recibir candesartan y el objetivo primario principal fue the mortalidad of causa cardiovascular u hospitalizacion por IC.